ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1402	National Cancer Institute	Html	en	Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.	T-cell lymphoblastic lymphoma 0.616756 mediastinal B-cell lymphoma 0.654258 Pediatric Non-Hodgkin Lymphoma 0.567507 mature B-cell 0.675642 Engl J Med 0.525188 B-cell non-Hodgkin lymphoma 0.746462 children 0.65412 mature B-cell leukemia 0.544897 cell lymphoma outcome 0.543686 lymphoblastic lymphoma stage 0.540387 pediatric-type follicular lymphoma 0.574777 large B-cell lymphomas 0.528398 large cell lymphoma 0.779097 pediatric anaplastic lymphoma 0.540067 adolescents 0.539146 Burkitt lymphoma 0.638477 mediastinal large B-cell 0.573557 childhood B-cell non-Hodgkin 0.52722 diffuse large b-cell 0.665879 anaplastic large-cell lymphoma 0.616485 center-derived B-cell lymphoma 0.609426 Burkitt lymphoma incidence 0.577758 cell lymphoma cases 0.534062 Leuk Lymphoma 0.529329 large B-cell lymphoma 0.815777	cell lymphoma patients 0.528087 mature B-cell lymphoma 0.609056 et al. 0.801373 Br J Haematol 0.629196 Cairo MS 0.571856 primary mediastinal B-cell 0.5557 Pediatr Blood Cancer 0.817055 childhood B-cell 0.532059 diffuse large-B-cell lymphoma 0.523303 Secondary non-Hodgkin lymphoma 0.572995 mature B-cell non-Hodgkin 0.643468 lymphoblastic lymphoma 0.618923 Abstract 0.750082 cancer group 0.553869 lymphoma 0.902345 Clin Oncol 0.644225 childhood non-Hodgkin lymphoma 0.549011 high-stage Burkitt lymphoma 0.543865 B-cell lymphoma subgroups 0.565819 non-hodgkin lymphoma 0.766463 recurrent non-Hodgkin lymphoma 0.543912 anaplastic large cell 0.660109 oncology group 0.53775 Burkitt-like lymphoma 0.528197	CLICK HERE
1451	National Cancer Institute	Html	null	Unusual Cancers of Childhood Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of unusual cancers of childhood such as cancers of the head and neck, chest, abdomen, reproductive system, skin, and others.			CLICK HERE
1489	National Cancer Institute	Html	en	Salivary Gland Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of salivary gland cancer.	salivary gland carcinoma 0.511905 salivary duct carcinoma 0.495372 salivary neoplasms 0.436633 salivary gland neoplasms 0.699057 salivary gland tumors 0.679256 Oral Surg Oral 0.463588 Oral Med Oral 0.447637 Med Oral Pathol 0.44551 Labial salivary gland 0.469995 malignant salivary gland 0.526645 salivary gland neoplasm 0.484554 acinic cell carcinoma 0.43649 Salivary Gland Disease 0.467146 minor salivary glands 0.598035 epithelial salivary gland 0.497367 minor salivary glands. 0.45198 Gnepp DR 0.473942 Auclair PL 0.442506 salivary gland tissue 0.459874 Ellis GL 0.451621 salivary gland 0.899362 mesenchymal salivary gland 0.475624 mucoepidermoid carcinoma 0.443769 intraoral minor salivary 0.423491	Salivary gland tumours 0.500385 salivary gland lesion 0.478189 intraoral salivary glands 0.465746 parotid gland 0.430561 adenoid cystic carcinoma 0.455777 PUBMED Abstract 0.424085 major salivary glands 0.755909 salivary gland neoplasms. 0.489141 salivary gland register 0.455761 minor salivary gland 0.596497 common salivary gland 0.491012 Central salivary gland 0.46762 salivary gland accessions 0.477176 cell carcinoma 0.493942 salivary gland regions 0.454552 salivary gland sites 0.489141 Abstract 0.471491 salivary glands. 0.452306 salivary glands 0.905936 Surg Oral Med 0.463412 salivary gland tumor 0.497715 major salivary gland 0.545945 major salivary glands. 0.437313 salivary gland origin 0.593941	CLICK HERE
1498	National Cancer Institute	Html	en	Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of lip and oral cavity cancer.	retromolar trigone 0.457467 lesions 0.51335 cone radiation therapy 0.449302 stage IV tumors 0.388096 station nodes 0.404586 radiation therapy. 0.414397 lip 0.39553 larger lesions 0.408688 oral cavity cancer 0.391261 upper gingiva 0.475854 local recurrence 0.42994 early lesions 0.429301 World Health Organization 0.457603 patients 0.399778 early cancers 0.501066 small cancers 0.408462 interstitial radiation sources 0.430653 advanced cancers 0.459827 neck cancers 0.384982 lymph nodes 0.55579 radiation therapy 0.932988 cancers 0.524279 lymph node drainage 0.410464 anterior tongue 0.427579 treatment 0.469588	radiation modifiers 0.407878 lichen planus 0.388656 radiation oncologists 0.396567 posterior cervical nodes 0.416429 oral cavity tumors 0.396446 cervical lymph nodes 0.491468 distant metastases 0.456495 regional lymph node 0.41022 Precancerous lesions 0.394835 buccal mucosa 0.38527 radical radiation therapy 0.447851 moderately advanced lesions 0.488166 external-beam radiation therapy 0.451492 oral cavity cancers 0.431571 cosmetic results 0.421228 radiation treatment 0.406818 stage 0.394996 hard palate 0.551429 local control rates 0.433778 oral cavity 0.569458 regional lymph nodes 0.478345 radiation oncologist 0.475855 Small superficial cancers 0.415309 squamous cell carcinoma 0.47595	CLICK HERE
1830	National Cancer Institute	Html	es	Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica.	imatinib treatment 0.309815 associated with 0.307718 Saglio G 0.311488 Imatinib plus 0.308886 mayoría imatinib 0.309903 with chronic myeloid 0.371977 Sin embargo 0.315782 Kantarjian HM 0.372759 standard-dose imatinib therapy 0.309084 myeloid leukemia patients 0.32923 Cortes JE 0.313764 chronic myeloid leukemia 0.996248 or imatinib 0.327327 myelogenous leukemia patients 0.309285 Philadelphia chromosome-positive 0.307544 TCM alogénico 0.343658 chronic myelomonocytic leukemia 0.306491 patients with chronic 0.376511 Rosti G 0.305694 leucemia mielógena 0.3214 stem cell transplantation 0.309631 chronic myelogenous leukemia 0.537094 with imatinib 0.31893 Guilhot F 0.305867 vs imatinib 0.308365	Chronic Leukemia 0.308312 Versus Imatinib Study 0.318542 patients with philadelphia 0.308802 dasatinib or imatinib 0.311418 versus imatinib 0.331295 Jabbour E 0.308732 patients with 0.421072 myeloid leukemia treated 0.313347 Treatment-Naïve Chronic Myeloid 0.309823 marrow transplantation 0.313614 leukemia treated with 0.314928 Dasatinib Versus Imatinib 0.321251 bone marrow transplantation 0.310388 Leukemia Patients Trial 0.308496 newly diagnosed chronic 0.341689 treated with imatinib 0.310526 imatinib depends 0.308315 imatinib versus 0.310194 chronic granulocytic leukemia 0.306345 tirosina cinasa 0.443764 Clin Oncol 0.407181 bone marrow 0.312247 myelogenous leukemia with 0.307043 treated with 0.317153	CLICK HERE
1917	National Cancer Institute	Html	es	Tratamiento del cáncer de vesícula biliar (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vesícula biliar.	terapia paliativa mejora 0.52497 pequeñas incisiones 0.470446 siguientes procedimientos 0.45044 estadio iv 0.621294 siguientes aspectos 0.501569 estadio ii 0.777223 flexible llamada endoprótesis 0.532683 siguientes razones 0.497295 siguientes tipos 0.464265 vía oral 0.447019 rayos x 0.470622 ondas sonoras 0.475252 estadio iva 0.502715 National Cancer Institute 0.448229 siguientes riesgos 0.438065 Instituto Nacional 0.69474	estadio iiia 0.507081 PDQ Tratamiento 0.493466 siguientes problemas 0.500188 presente sección 0.442764 partes distantes 0.453382 Physician Data Query 0.580893 estadio i 0.784786 siguientes sitios 0.573736 biliar libera bilis 0.930425 antígeno carcinoembrionario 0.484555 colangiopancreatografía retrógrada 0.478582 ecografía abdominal 0.479387 intestino delgado.ampliar anatomía 0.581644 siguientes enlaces 0.446364 laparoscopia ayuda 0.464844	CLICK HERE
1925	National Cancer Institute	Html	es	Tratamiento del cáncer de hipofaringe (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de hipofaringe.	Neck Cancer 0.247768 siguientes procedimientos 0.753135 siguientes aspectos 0.304732 rayos x 0.282557 pequeñas marcas 0.25053 estadio ivc 0.310167 enlace drugs approved 0.28833 estadio iva 0.312892 vías respiratorias 0.282072 National Cancer Institute 0.233317 siguientes opciones 0.237415 siguientes riesgos 0.225706	realidad células 0.310814 cuerpo.ampliar radioterapia 0.360468 Instituto Nacional 0.267315 hormonas tiroideas 0.252232 malla ayuda 0.248727 PDQ Tratamiento 0.272276 paciente fuma 0.301748 Physician Data Query 0.341971 estadio i 0.315197 ganglio linfático mide 0.903903 glándula tiroidea 0.554743 siguientes estadios 0.417752	CLICK HERE
2964	National Cancer Institute	Html	en	E-Cigarettes	If you’re thinking about using an e-cig, here are three things you should know.	hookah water pipe 0.494728 large premium cigars 0.459683 oral tobacco 0.537822 greater risks 0.403027 cancer-causing substances 0.387897 chemical additives 0.392918 burning cigarette 0.414008 throat cancer 0.383899 lung cancer 0.382731 tobacco 0.978071 supportive friends 0.453267 cancer-causing chemicals 0.389232 hookah smoke 0.446625 Cigar smoke 0.40643 greater health issues 0.438887 carbon monoxide 0.384792 cigar tobacco 0.526627 paper wrapping 0.393371 leaf tobacco 0.522574 tobacco products 0.765605 harm brain development 0.443591 high risk 0.381422 little filtered cigars 0.462027 older siblings 0.385847 Hookah tobacco 0.577414	healthy way 0.432788 Nicotine exposure 0.405523 toxic chemicals 0.388306 harmless water vapor 0.448644 potentially harmful chemicals 0.482948 high levels 0.460808 health consequences 0.391113 cigarette smoke 0.424559 cigarette smoking 0.578732 heart disease 0.388527 DipfreeTXT program 0.386418 vape pens 0.380351 hookah smoking 0.490187 multiple tobacco products 0.584428 spitting tobacco 0.542435 mouth cancer 0.379991 size—from smaller cigars 0.460695 cigarette tobacco 0.544703 Cigar users 0.389386 quitSTART app 0.388192 e-cigarettes 0.388072 smokeless tobacco 0.780551 risks 0.529273 health risks 0.470569	CLICK HERE
3579	National Cancer Institute	Html	en	Cancer Health Disparities Research	NCI is addressing cancer health disparities through its efforts in basic research, community-level programs, and more.	cancer treatment 0.363689 cancer control continuum—from 0.369693 health care disparities 0.45285 American Cancer Society 0.373854 Breast Cancer Genetic 0.374611 NCI research programs 0.364956 cancer health disparities—such 0.406746 colorectal cancer 0.373832 American Breast Cancer 0.39202 Colorectal Cancer Outreach 0.36747 public health officials 0.365199 breast cancer outcome 0.373209 clinical cancer research 0.388692 Reduce Cancer Health 0.386549 health care facilities 0.400047 Breast Cancer Consortium 0.371087 population groups 0.362749 African American Breast 0.367467 care delivery research 0.356797 public health communities 0.394704 cancer health disparities 0.942995 NCI-Designated Cancer Centers. 0.367758 Documented cancer health 0.404937 certain racial/ethnic populations 0.356837 cancer research community 0.391405	Cancer Health Equity 0.385722 cancer research continuum 0.381244 cancer prevention 0.353808 prostate cancer deaths 0.379501 health disparities research 0.467802 cancer research 0.471213 African American men 0.354676 cancer screenings 0.355012 cancer screening rates 0.368257 cancer care—from access 0.379244 Breast Cancer Epidemiology 0.371467 African American women 0.401312 complex health care 0.371446 advanced cancer diagnoses—in 0.382581 community health educators 0.353702 breast cancer 0.431984 cancer care delivery 0.39176 cancer disparities 0.490093 NCORP cancer care 0.377954 experience cancer-related health 0.363186 cancer clinical trials 0.389742 cancer risk 0.352747 cancer death rates 0.384903 cancer incidence 0.357189	CLICK HERE
15634	National Cancer Institute	Html	en	Step 3: Peer Review and Funding Outcomes	The NCI review process seeks to achieve a balanced grant portfolio, that addresses scientific priorities. Learn about NCI’s peer review for grant applications.	Final funding decisions 0.68801 conservative funding range 0.692235 Funding Opportunity Announcement 0.669325 grant applications 0.543909 grant review cycle 0.655483 previously reviewed submissions 0.591298 scientific research community 0.67817 grants management specialist 0.65539 JIT requirements 0.569359 NCI budget 0.675257 specific grant application 0.663769 funding guidelines 0.594989 Grants Policy Manual 0.654435 grants management 0.718868 Resubmission Applications 0.561239 additional information 0.630031 funding mechanisms 0.587684 future funding 0.591477 preliminary funding allocations 0.74522 JIT Procedures 0.570833 program allocations 0.582504 program priorities 0.540659 NCI division 0.672087 grants management staff 0.632016 JIT information 0.763408	review percentile/impact score 0.647883 NIH Policy 0.59572 responsible NIH official 0.747181 Peer Review process 0.887529 NCI Scientific Program 0.984221 NCI Peer Review 0.873194 important scientific priorities 0.646164 nih peer review 0.942228 Program Leadership Committee 0.639488 subsequent new application 0.637696 unsuccessful initial submission 0.60519 scientific program staff 0.658004 Scientific Review 0.61867 promising scientific opportunities 0.644998 administrative review 0.543867 following JIT information 0.687226 NCI grants process 0.840796 unsuccessful initial application 0.638737 scientific merit 0.540216 Scientific Program Leadership 0.821474 funding decisions 0.80612 dual review process 0.70096 timely review 0.580483 Public Health Service 0.644114	CLICK HERE